RxDoctor Payments Data

Theodore Leng, MD

Retina Specialist · Stanford, CANPI 1144438987

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $195,837 of the $222,582 with a category attached, or 88.0%. It is spread thinly across 24 manufacturers, the largest accounting for just 17.8%. Among retina specialist clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$222,582in general payments, 2019–2025

Across 178 payments — averaging $1250.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Topcon Healthcare, Inc.$40K
  • Boehringer Ingelheim International GmbH$36K
  • Genentech, Inc.$34K
  • Alcon$34K
  • Regeneron Healthcare Solutions, Inc.$27K
  • F. Hoffmann-la Roche AG$23K
  • plus $30K from 18 others
$157,641in research payments, 2019–2025

Across 97 payments — averaging $1625.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$62K
  • Astellas Pharma Global Development$43K
  • Topcon Corporation$29K
  • Genentech, Inc.$14K
  • Regeneron$10K

What the payments were for

  • Consulting fees$195,83788%
  • Speaking & faculty fees$4,1742%
  • Travel & lodging$16,5087%
  • Food & beverage$6,0443%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$222,582 in reported general payments places this provider in the 90th percentile of 187 retina specialist providers in California.

See all retina specialist providers in California

Medicare billing

Part B allowed, 2024
$432,359
Medicare patients
1,168
Services billed
5,898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Azelastine Hcl54$1,829
Prednisolone Acetate24$756
Ketorolac Tromethamine24$476

Paid to pharmacies, not to this prescriber.

Other retina specialist in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →